OpenScience.ink

1 week ago • Cardiovascular & hematological disorders drug targets

Using SGLT-2 Inhibitors and GLP-1 Receptor Agonists to Manage Metabolic Syndrome in Type 2 DiabetesSGLT-2 Inhibitors and GLP-1 Receptor Agonists in Managing Metabolic Syndrome Among Patients with Type 2 Diabetes Mellitus - A Narrative Review.

Article

1 week ago • JGH open : an open access journal of gastroenterology and hepatology

How Medicines for Treating Obesity Have Changed Over TimeThe Evolution of Medications for Obesity Management.

📖 Top 50% JournalArticle

2 weeks ago • Cardiology in review

Safety and Blood Sugar Control of Liraglutide Around Heart SurgerySafety and Glycemic Efficacy of Perioperative Liraglutide in Cardiac Surgery: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

📖 Top 50% JournalArticle

2 weeks ago • Acta medica portuguesa

Changes in Antidiabetic Drug Prescribing Across Regions in Portugal Over Eight Years (2017–2024)[Regional Trends in Antidiabetic Drug Prescribing in Portugal: Eight Years of Nationwide Real-World Evidence (2017 - 2024) (TREND-8 REGIONS Study)].

English Abstract

2 weeks ago • Indian journal of pharmacology

Current and new drug treatments for obesityPharmacological management of obesity: Current landscape and emerging therapies.

📖 Top 50% JournalArticle

2 weeks ago • Nursing standard (Royal College of Nursing (Great Britain) : 1987)

Guide to Weight Loss Medicines and Practical Tips for PatientsOverview of weight loss medicines and practical advice for patients.

Article

3 weeks ago • Diabetology international

Misuse of GLP-1 weight-loss drugs: moving from correct prescribing to effective weight lossInappropriate use of GLP-1-based antiobesity medications: beyond appropriate drug use toward appropriate weight reduction.

📖 Top 50% JournalEditorial

3 weeks ago • Journal of dual diagnosis

Potential of GLP-1 Receptor Agonists and DPP4 Inhibitors in Treating Opioid AddictionExploring The Role of GLP-1 Receptor Agonists and DPP4 Inhibitors in the Treatment of Opioid Use Disorder: A Scoping Review.

📖 Top 50% JournalArticle

3 weeks ago • Cardiovascular & hematological disorders drug targets

Vein Pressure Build-Up in Metabolic Heart Disease and Possible Indirect Effects of Dual Incretin DrugsVenous Congestion in Metabolic Heart Disease: Potential Indirect Role of Dual Incretin Agonists.

Article

3 days ago • Zentralblatt fur Chirurgie

Uses and Side Effects of GLP-1 Receptor Drugs in Urinary and Male Reproductive Health[GLP-1 Receptor Agonists in Urology and Andrology: Indications, Opportunities and Clinically Relevant Adverse Effects].

English Abstract

1 week ago • Revue medicale suisse

Blood pressure effects of strong GLP-1 and GIP hormone-like drugs[Blood pressure effects of potent GLP-1 and GIP analogues].

English Abstract

1 week ago • Zhonghua yi xue za zhi

Glucagon-like peptide-1 receptor agonists: from controlling metabolism to treating rheumatic diseases[Glucagon-like peptide-1 receptor agonists: from metabolic regulation to rheumatic disease therapy].

English Abstract

yesterday • JCEM case reports

Repeated eyelid bumps linked to tirzepatide treatment: a case seriesSimultaneous and recurrent hordeola and chalazia associated with tirzepatide therapy: a case series.

Case Reports

2 days ago • JCEM case reports

Long-term weight loss over 100 kg using step-by-step hormone-based treatment in Prader-Willi syndromeSustained weight loss exceeding 100 kg with sequential incretin-based therapy in Prader-Willi syndrome.

Case Reports

2 days ago • JCEM case reports

Postmenopausal bleeding linked to semaglutide poses a diagnosis challengePostmenopausal bleeding associated with semaglutide: a diagnostic challenge.

Case Reports

1 week ago • Annals of medicine and surgery (2012)

Sudden inflammation of the pancreas after semaglutide treatment: a case reportAcute pancreatitis following semaglutide therapy: a case report.

Case Reports

2 weeks ago • JCEM case reports

Tirzepatide treatment for low blood sugar after gastric bypass surgery: 3 case reportsTirzepatide for treatment of postbariatric hypoglycemia after Roux-en-Y gastric bypass: a report of 3 cases.

Case Reports

2 weeks ago • JCEM case reports

Lack of response to tirzepatide followed by response to semaglutide in people with moderate obesityTirzepatide non-response with subsequent semaglutide response in class 2 obesity.

Case Reports

5 days ago • Annals of the New York Academy of Sciences

How Nearby Cell Signals in the Pancreas Affect Glucagon Release at Low, Normal, and High Blood Sugar LevelsIntra-Islet Paracrine Regulation of Glucagon Secretion During Hypoglycemia, Euglycemia, and Hyperglycemia.

Fulltext (Open License)Article

1 week ago • Cureus

Brain and mental effects of diabetes drugs acting on GLP-1 receptors in schizophrenia-related disorders: A systematic reviewNeuropsychiatric Effects of Glucagon-Like Peptide-1 Receptor Agonists in Schizophrenia-Spectrum Disorders: A Systematic Review.

Article

1 week ago • Diabetes & metabolism journal

Addressing Muscle Loss Risks in Treatments That Lower Blood SugarBeyond Fat Loss: Addressing the Sarcopenia Challenge of Incretin-Based Therapies.

Article

2 weeks ago • npj metabolic health and disease

Higher semaglutide doses linked to fewer mental health problems regardless of weight lossHigher semaglutide dose is associated with lower neuropsychiatric event incidence independent of weight loss.

Article

1 week ago • Clinical science (London, England : 1979)

How the gut detects fat and triggers hormone releaseHow lipid ingestion is sensed: the mechanisms underlying intestinal hormone secretion.

Article

1 week ago • Frontiers in stroke

Using SGLT2 inhibitors and incretin-based drugs for heart and metabolism health after strokeCardiometabolic drugs after stroke: time to embrace SGLT2 inhibitors and incretin-based therapies?

Article

1 week ago • Diabetes, obesity & metabolism

Study Plan and Starting Data for Using GLP-1 Drugs After Weight-Loss SurgeryGLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Trial: Rationale, Design and Baseline Characteristics.

Article

1 week ago • Cardiovascular diabetology. Endocrinology reports

GLP-1 receptor agonists may protect the heart, kidneys, and metabolism beyond blood sugar controlGLP-1 receptor agonists beyond glycemic control: integrated cardio-renal-metabolic protection across the cardiovascular kidney metabolic continuum.

Article

2 weeks ago • Obesity reviews : an official journal of the International Association for the Study of Obesity

How Gut Bacteria and Body Chemicals Relate to Obesity and Treatments at Different AgesMicrobiome and Metabolomics in Obesity: Advances in Understanding and Interventions Across the Lifespan.

Article

2 weeks ago • Cardiovascular diabetology. Endocrinology reports

Heart and metabolism effects of once-weekly IcoSema in adults with type 2 diabetesCardiometabolic outcomes of once-weekly IcoSema in adults with type 2 diabetes: systematic review and meta-analysis of the COMBINE trials.

Article

2 weeks ago • Diabetes, obesity & metabolism

Blood Sugar Changes After Stopping Semaglutide in Adults with Type 1 Diabetes Using Automated Insulin DeliveryGlycaemic Changes After Semaglutide Discontinuation in Adults With Type 1 Diabetes Using Automated Insulin Delivery: Analysis of the ADJUST-T1D Extension Study.

Article

2 weeks ago • British journal of pharmacology

Oleoylethanolamide's potential for treating obesity and related health problemsThe ongoing oleoylethanolamide story: Therapeutic implications in the control of obesity and its comorbidities.

Article

← prevpage 11 of 14next →

GLP-1 Therapies Research Papers